Focus Diagnostic Medicine News

Dr. Donald Landry Joins The Focus Diagnostic Medicine Advisory Board

Focus Diagnostic Medicine has announced that Donald W. Landry, M.D., Ph.D., has joined its Advisory Board. Dr. Landry is Chairman of the Department of Medicine, Samuel Bard Professor, and Chief of the Division of Experimental Therapeutics at Columbia University’s College of Physicians and Surgeons (P&S) and Physician-in-Chief at New York Presbyterian Hospital/Columbia. He was previously Chief of the Division of Nephrology at P&S. Dr. Landry is known as an eclectic innovator whose work cuts across drug discovery, medicinal chemistry, protein engineering, neuroendocrine physiology, nephrology, cardiology, toxicology, and a number of other fields.

"Don Landry is recognized around the world as a visionary physician-leader. It is an honor to have him on the FDM Advisory Board. His insight and judgment represent important resources for our growing organization," said Andrew H. Segal, M.D., CEO of Focus Diagnostic Medicine.

Focus Diagnostic Medicine (“FDM”) specializes in helping patients from around the world who are clearly medically ill but have been unable to obtain a diagnosis elsewhere. FDM’s team of diagnostic physicians focuses on patients who are likely to have rare or frequently misdiagnosed conditions or more common conditions presenting in an atypical way, as well as patients who have unexplained, new symptoms arising on the background of a complex medical history. FDM aims to provide frustrated patients with an unparallelled level of attention and expertise to help them find the road back to health and serenity.

Focus Diagnostic Medicine In Alliance With Columbia's College Of Physicians And Surgeons

Focus Diagnostic Medicine (FDM) has entered into a strategic alliance with the Department of Medicine at Columbia University's College of Physicians and Surgeons, one of the world's preeminent medical institutions. The alliance will provide:

  • Columbia faculty affiliations for FDM's elite team of physicians.
  • Rapid access to diagnostic procedures through Columbia's medical faculty located in a new midtown Manhattan facility, a key benefit for FDM's global patient clientele, as well as access to Columbia's hospitalist service.
  • FDM tie-in to Columbia's electronic medical record system.
  • Opportunities for Columbia trainees to rotate through FDM.

Dr. Andrew H. Segal, CEO of Focus Diagnostic Medicine, commented, "This is an exciting development for both FDM and Columbia. We anticipate that our patients will benefit tremendously from this alliance between one of America's most established medical faculties and one of its most innovative private clinical programs."

Focus Diagnostic Medicine (“FDM”) specializes in helping patients from around the world who are clearly medically ill but have been unable to obtain a diagnosis elsewhere. FDM’s team of diagnostic physicians focuses on patients who are likely to have rare or frequently misdiagnosed conditions or more common conditions presenting in an atypical way, as well as patients who have unexplained, new symptoms arising on the background of a complex medical history. FDM aims to provide frustrated patients with an unparallelled level of attention and expertise to help them find the road back to health and serenity.

Dr. Arnold Weinberg Joins The Focus Diagnostic Medicine Advisory Board

Arnold N. Weinberg, M.D. has joined the Advisory Board for Focus Diagnostic Medicine. Dr. Weinberg is Professor of Medicine at Harvard Medical School and Senior Physician at Massachusetts General Hospital. Dr. Weinberg has served the School and Hospital in a wide variety of capacities. At the Medical School, he was responsible for courses in microbiology, pathophysiology of infectious diseases, and clinical infectious disease. At Massachusetts General Hospital, he was Vice Chair of Medicine, served as an associate Firm Chief, and, for over 4 decades, has taught and consulted in infectious diseases and general medicine. In addition, he served as Medical Director at Massachusetts Institute of Technology, has consulted extensively at MIT's Lincoln Laboratory, and was a longstanding member of the Board of Directors at the Whitehead Institute for Biomedical Research. Dr. Weinberg has been a Director of Thermo Bioanalysis Corp. and a member of the Scientific Advisory Board of Innovative Biosensors Inc. He has particular expertise in the zoonoses, diseases transmitted from animals to humans, and has presented Grand Rounds at the NIH as part of the Clinical Center's "Great Teachers" program.

Andrew H. Segal, M.D., CEO of Focus Diagnostic Medicine, commented, "Few people have Arnie Weinberg's breadth of experience in medicine and healthcare, or his wisdom. His appointment as an advisor marks an important milestone for our organization."

Dr. Weinberg joins the following eminent leaders on the FDM advisory board:

  • Cornelius F. Boerkoel, M.D., Ph.D.- Dr. Boerkoel is Director of the NIH's Undiagnosed Disease Program Translational Laboratory in Bethesda. In that capacity, he has developed innovative clinical, laboratory, and informatics-based approaches to the patient who has eluded diagnosis. He is also recognized as a worldwide leader in the genomic analysis of patients who have mysterious symptoms. In his career, Dr. Boerkoel has taken 3 different rare diseases from evaluation of a single patient through early-stage drug development.
  • George H. Sack, Jr,. M.D., Ph.D.- Associate Professor of Medicine, Johns Hopkins University. Founder and former Director, Johns Hopkins Executive Health Program, which he grew to a volume of 1300 patients per year. Medical Director of Johns Hopkins USA, Hopkins' national referral program. Medical geneticist, trained under Victor McKusick and McGehee Harvey, specializing in rare diseases.
  • Michael V. Seiden, M.D., Ph.D.- Chief Executive Officer of the world-renowned Fox Chase Cancer Center in Philadelphia.
  • Thomas R. Spitzer, M.D.- Professor of Medicine, Harvard Medical School. Chief of the Walter Bauer firm, Department of Medicine, Massachusetts General Hospital. Director of Bone Marrow Transplantation, Massachusetts General Hospital.

Focus Diagnostic Medicine (“FDM”) specializes in helping patients from around the world who are clearly medically ill but have been unable to obtain a diagnosis elsewhere. FDM’s team of diagnostic physicians focuses on patients who are likely to have rare or frequently misdiagnosed conditions or more common conditions presenting in an atypical way, as well as patients who have unexplained, new symptoms arising on the background of a complex medical history. FDM aims to provide frustrated patients with an unparallelled level of attention and expertise to help them find the road back to health and serenity.